Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07114939 · ClinicalTrials.gov registry record · Phase 1
FTT PET/CT in Pancreatic Neuroendocrine Tumors
A Phase 1 study of Neuroendocrine Carcinoma Metastatic and Pancreatic Tumors, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07114939 is a Phase 1 study of Neuroendocrine Carcinoma Metastatic and Pancreatic Tumors that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07114939, a Phase 1 study of Neuroendocrine Carcinoma Metastatic and Pancreatic Tumors, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.
Conditions Studied
Interventions
- DRUG [18F]FluorThanatrace
Study Locations (1)
Pennsylvania
- University of Pennsylvania, Perelman Center for Advanced Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07114939
The ClinicalTrials.gov registry entry for NCT07114939 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuroendocrine Carcinoma Metastatic appearing as the primary indexed condition, and to 1 intervention - of which [18F]FluorThanatrace is the first listed.
NCT07114939 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07114939 about?
NCT07114939 is a clinical study titled "FTT PET/CT in Pancreatic Neuroendocrine Tumors". A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging asse...
What is the current status of trial NCT07114939?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-10-01. Estimated completion is 2027-09.
What conditions does trial NCT07114939 study?
This clinical trial studies the following conditions: Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors.
What interventions are being tested in trial NCT07114939?
The interventions under investigation include: [18F]FluorThanatrace (DRUG).
Who is sponsoring clinical trial NCT07114939?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07114939 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Neuroendocrine Carcinoma Metastatic
All registered trials for this condition
Pancreatic Tumors
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.